Scientific Outputs

Since 1991, the key priority of the AGITG has been to undertake quality research that is centred on patient care and improves medical practice in the treatment of gastro-intestinal cancer.

The AGITG and its members contribute to various journals, publications and conference presentations in Australia and worldwide.

AGITG Journal Articles 1999-2018 AGITG Presentations 1999-2018

 

Share

Journal Articles

A La CaRT
Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Davies L, Wilson K, Hague W, Simes J. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA 2015; 314(13): 1356–1363.
ABC
Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, Gebski V, Miller D, Shannon J. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology 2011; 67(3): 519–525.
AG0001H
Nowak AK, Cebon J, Hargreaves C, Dhillon H, Findlay M, Gebski V, Stockler MR. Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology 2008; 4: 55-67.

Cebon J, Hargreaves C, Stockler M, Nowak A, Dhillon H, Dickman B, Gebski V; Australasian Gastro-Intestinal Trials Group (AGITG) AG0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer 2006; 95(7): 853–861.

Nowak A, Chow P, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. European Journal of Cancer 2004; 40(10): 1474-1484.

Nowak A, Findlay M, Culjak G, Stockler M. Tamoxifen for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2004; (3): CD001024

AG9401
Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. British Journal of Cancer 2005; 93: 1235–1243.
AG9601
Findlay M, Storey D, Gebski V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Truskett P, Goldstein D; on behalf of the AGITG. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. Australian and New Zealand Journal of Surgery 2007; 77(4): 247–252.
AG9802
Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Annals of Oncology 2001; 12(12): 1711-1720.
ARCAD
Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology 2016; 17(12): 1709–1719.
ARCTIC
Ransom D, Wilson K, Fournier M, Simes RJ, Gebski V, Yip D, Tebbutt N, Karapetis CS, Ferry D, Gordon S, Price TJ. Final results of Australasian Gastro-Intestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Annals of Oncology 2014; 25(1): 117–121. 13.
ATTAX
Tebbutt NC, Cummins MM, Sourjina T, Strickland AH, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer 2010; 102: 475–481.
ATTAX2
Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ, on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer 2013; 108(4): 771–774.
ATTAX3
Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, Gebski V. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer 2016; 114(5): 505-509.
C06
Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. Journal of Clinical Oncology 2007; 25(4): 424–430.

Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral Uracil and Tegafur Plus Leucovorin Compared with Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Journal of Clinical Oncology 2006; 24(13): 2059-64.

C07
Yothers G, O’Connell M, Allegra C, Kuebler J, Colangelo L, Petrelli N, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. Journal of Clinical Oncology 2011; 29(28): 3768-3774.

Kuebler JP, Colangelo L, O’Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 2007; 110(9): 1945–1950.

Kuebler JP, Wieand S, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. Journal of Clinical Oncology 2007; 25(16): 2198–2204.

Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O’Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology 2007; 25(16): 2205–2211.

CO.17
Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O’Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A. Fc-gamma receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. Clinical Cancer Research 2016; 22(10): 2435–2444.

Brule SY, Jonker DJ, Karapetis CS, O’Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. European Journal of Cancer 2015; 51(11): 1405-1414.

Jonker D, Karapetis C, Harbison C, O’Callaghan C, Tu D, Simes R, Malone D, Langer C, Tebbutt N, Price T, Shapiro J, Siu L, Wong R, Bjarnason G, Moore M, Zalcberg J, Khambata-Ford S. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer 2014; 110(3): 648–55.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA. PIK3CA, BRAF and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. Clinical Cancer Research 2014; 20(3): 744–753.

Sommeijer DW, Karapetis CS, Zalcberg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O’Callaghan CJ. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta Oncologica 2014; 53(7): 877–884.

Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, O’Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, Green GA 4th. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. Archives of Pathology & Laboratory Medicine 2013; 137(6): 820–827.2

Vickers MM, Karapetis CS, Tu D, O’Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology 2013; 24(4): 953–960.

Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck DA, Whittom R, Langer C, O’Callaghan CJ. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology 2011; 22(1): 118–126.

De Roock S, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O’Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of Kras p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304(16): 1812–1820.

Au HJ, Karapetis CS, O’Callaghan CJ, Tu D, Moore MJ, Zalcberg J, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ. Health-related quality of life in advanced colorectal cancer patients treated with cetuximab: overall and Kras-specific results of the NCIC CTG and AGITG CO.17 trial. Journal of Clinical Oncology 2009; 27(11): 1822–1828.

Mittmann N, Au HJ, Tu D, O’Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group–Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. Journal of the National Cancer Institute 2009: 101(17): 1182–1192.

Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine 2008; 359(17): 1757–1765.

Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine 2007; 357(20): 2040–2048.

CO.20

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O’Callaghan CJ, NCIC Clinical Trials Group, Australasian Gastrointestinal Trials Group. Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. Cancer 2014; 120(2): 181–189.

Siu L, Shapiro J, Jonker D, Karapetis C, Zalcberg J, Simes J, Couture F, Moore M, Price T, Siddiqui J, Nott L, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski N, Haydon A, Walters I, Ringash J, Tu D, O’Callaghan C. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. Journal of Clinical Oncology; 31(19): 2477-2484.

Da Vinci
Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebski V, Zalcberg J, Simes RJ. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. European Journal of Cancer 2011; 47(12): 1826–1836. 1.
E9288
Kemeny M, Adak S, Gray B, Macdonald J, Smith T, Lipsitz S, Sigurdson E, O’Dwyer P, Benson Ar. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. Journal of Clinical Oncology 2002; 20(6): 1499–1505.
EORTC 40983
Tanis E, Julie C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, Sorbye H, Bechstein W, Schlag P, Fisseler A, Ruers T. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. European Journal of Cancer 2015; 51(17): 2708–2717.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, for the EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncology 2013; 14(12): 1208–1215.

Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK (CRUK); Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Annals of Surgery 2012; 255(3): 534–539.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371(9617): 1007–1016.

EORTC 62005
Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schoffski P, Leyvraz S, Italiano A, Grunwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litiere S, Marreaud S, van der Graaf W, Gronchi A, Verweij J. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. Journal of Clinical Oncology. Published online 1 Apr 2017.
EORTC 62005
Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, Casali PG, Maki RG, Cioffi A, McArthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer 2015; 51(7): 852-860.

Hohenberger P, Bonvalot S, Litiere S, Rutkowski P, van Coevorden F, Meeus P, Marréaud S, Raventos VA, Kotasek D, Padbury R, Van der Graaf W, Gronchi A. Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross-match comparison in the EORTC intergroup study 62005, aimed at assessing the clinical activity of imatinib at two dose levels in patients with unresectable or metastatic GIST Connective Tissue Oncology Society; 15–18 Oct 2014; Berlin.

MetaGIST: Gastrointestinal Stromal Tumor Meta-Analysis Group, Verweij J, Blay J, Debiec-Rychter M, Demetri G, Heinrich M, Borden E, Blanke C, Crowley J, Rankin C, Casali P, Von Mehren M, Fletcher C, Fletcher J, Owzar K, Zalcberg J, Simes J, Bramwell V. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. Journal of Clinical Oncology 2010; 28(7): 1247–1253.

Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the Intergroup EORTC-ISG-AGITG phase III trial. Journal of Clinical Oncology 2009;27(24): 3969–3974.

Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay J, Hogendoorn P, on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clinical Cancer Research 2009; 15(12): 4191-4198.

Sciot R, Debiec-Rychter M, Daugaard S, Fisher C, Collin F, Van Glabbeke M, Verweij J, Blay J-Y, Hogendoorn, PCW; on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australian Trials Group. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumors. An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. European Journal of Cancer 2008; 44; 1855–1860.

Verweij J, Casali PG, Kotasek D, LeCesne A, Reichard P, Judson IR, Issels R, Van Oosterom AT, Van Glabbeke M, Blay J-Y. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. European Journal of Cancer 2007; 43: 974–978.

Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I; On behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasian Gastro-Intestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. European Journal of Cancer 2006; 42(8): 1093–103.

Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali P, Pierotti M, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127(1): 294–299.

Van Glabbeke M, Verweij J, Casali PG, Simes J, Cesne AL, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC- IS G-AGITG). European Journal of Cancer 2006; 42(14): 2277–2285.

Goldstein D, Tan B, Rossleigh M, Haindl W, Walker B, Dixon J. Gastrointestinal stromal tumours: correlation of F-18-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment respons–an AGITG study. Oncology 2005; 69(4): 326-332.

Van Glabbeke M, Verweij J, Casali P, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom A, Goldstein D, Sciot R, Hogendoorn P, Brown M, Bertulli R, Judson I. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group–Australasian Gastro-Intestinal Trials Group Study. Journal of Clinical Oncology 2005; 23(24): 5795-5804.

Zalcberg J, Verweij J, Casali P, Le Cesne A, Reichardt P, Blay J, Schlemmer M, Van Glabbeke M, Brown M, Judson I, EORTC Soft Tissue and Bone Sarcoma Group tISGAG-ITG. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. European Journal of Cancer 2005; 41(12): 1751-1757.

Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichardt P, Blay J-Y, Issels R, van Oosterom A, Hogendoorn P, van Glabbeke M, Judson I, Bertulli R, Judson I, for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australian Gastro-intestinal trials group: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127–1134.

EORTC 62024
Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WTA, Zalcberg JR, Litière S, Blay J-Y. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. Journal of Clinical Oncology 2015; 33(36): 4276–4283.
ESPAC 1, ESPAC 3
Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Büchler MW. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. British Journal of Cancer 2009; 100(2): 246–250.
ESPAC 3
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler, MW; for the European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA.2010; 304(10): 1073–1081.

Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpe A, Bassi C, Büchler MW, and for the European Study Group for Pancreatic Cancer. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Journal of the National Cancer Institute 2014; 106(1): djt347.

Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, O’Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J, Izbicki JR, Mayerle J, Dervenis C, Oláh A, Butturini G, Lind PA, Middleton MR, Anthoney A, Sumpter K, Carter R, Büchler MW. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. Journal of Clinical Oncology 2014; 32(6): 504–512.

Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW, European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308(2): 147–156.

Gofurtgo

Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter, IWT, Hruby G, Horvath L, Bydder S, Undercill C, Harvey J, Gebski VJ; on behalf of the Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer 2012; 106(1): 61–69.
ICECREAM

Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E, Cetuximab alone or with irinotecan for resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomised phase II ICECREAM study, Clinical Colorectal Cancer (2018), doi: 10.1016/j.clcc.2018.06.002.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology 2016; 34(19): 2258–2264.

 

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer 2016; 16: 339.

IDEA

Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the idea analysis. Expert Review of Anticancer Therapy. 2018;18(4):339-349.

IG9401

Sjoquist K, Burmeister B, Smithers BM, Zalcberg JR, Simes J, Barbour A, Gebski V; on behalf of the Australasian Gastro-Intestinal Trials Group(AGITG). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology 2011; 12(7): 681–692.

Gebski V, Burmeister B, Smithers MB, Foo K, Zalcberg J, Simes J. Meta-analysis of the survival benefits from preoperative chemoradiation therapy and chemotherapy in oesophageal carcinoma. Lancet Oncology 2007; 8: 226–234.

Burmeister BH , Smithers BM , Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, for the Trans-Tasman Radiation Oncology Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology 2005; 6(9): 659–668.

IMPACT

Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial. Clinical Cancer Research 2015; 21(9): 2029-2037.
INTEGRATE

Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O’Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology 2016; 34(23): 2728-2735.
LAP07

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T, Mineur L, Chibaudel B, Bonnetain F, Louvet C. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 2016; 315(17): 1844–1853.
MAGIC

Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M, Scarffe J, Lofts F, Falk S, Iveson T, Smith D, Langley R, Verma M, Weeden S, Chua Y, for the MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2007; 355(1): 11-20
MAX

Schofield PE, Stockler MR, Zannino D, Tebbutt NC, Price TJ, Simes RJ, Wong N, Pavlakis N, Ransom D, Moylan E, Underhill C, Wyld D, Burns I, Ward R, Wilcken N, Jefford M. Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. Supportive Care in Cancer 2016; 24(1): 401–408.

Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann K, J. S, Weickhardt A, Wrin JW, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the Phase III AGITG MAX involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer 2015; 112: 963-970.

Roohullah A, Wong HLS, K.M., Gibbs P, FIeld K, Tran B, Shapiro J, McKendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World Journal of Gastroenterology 2015; 21(17): 5352-5358.

Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer 2015; 113(1): 37–45.

Bruhn MA, Townsend AR, Lee CK, Shivasami A, Price TJ, Wrin J, Arentz G, Tebbutt NC, Hocking C, Cunningham D, Hardingham JE, on behalf of the BHI in collaboration with AGITG. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer 2014; 135(3): 731–741.

Carter HE, Zannino D, Simes RJ, Schofield DJ, Howard K, Zalcberg JR, Price TJ, Tebbutt NC. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. European Journal of Cancer 2014; 50(3): 535–543.

Hocking C, Hardingham J, Broadbridge V, Townsend AR, Tebbutt N, Cooper J, Ruszkiewicz A, Lee C, Price TJ. Can we accurately report PTEN status in advanced colorectal cancer? BMC Cancer 2014; 14: 128.

Hurwitz HI, Tebbut NC, Kabbinavar F, Giantonio BJ, Guane ZZ, Michell L, Waterkamp D, Tabernerog J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18(9): 1004–1012.

Price T, Hardingham J, Lee C, Townsend A, Wrin J, Wilson K, Weickhardt A, Simes R, Murone C, Tebbutt N. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer receiving bevacizumab. Cancer Medicine 2013; 2(3): 277–285.

Price TJ, Zannino D, Wilson K, Simes J, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Annals of Oncology 2012; 23(6): 1353–1536.

Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. Journal of Clinical Oncology 2011; 29(19): 2675–2682.

Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ; on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology 2011; 22(8): 1834–1838.

Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua YJ, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab and mitomycin C in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomised phase III MAX study. Journal of Clinical Oncology 2010; 28(19): 3191–3198.

PA.3

Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O’Callaghan CJ, Jonker DJ, Ringash J, Goldstein D. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology 2016; 16(6): 1106-1112.

Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O’Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity, age and overall survival in patients with advanced pancreatic cancer—results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. European Journal of Cancer 2012; 48(10): 1434–1442.

PETACC6

Gormly KL, Coscia C, Wells T, Tebbutt N, Harvey JA, Wilson K, Schmoll HJ, Price T. MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial. Journal of Medical Imaging and Radiation Oncology 2016; 60(5): 607–615.
QUASAR2

Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncology 2016; 17(11): 1543–1557.

Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent DJ, Green E, McLeod H, Zanger UM, Schwag M, Seymour MT, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley RS, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. Journal of Clinical Oncology 2014; 32(10): 1031–1039.

SCOT

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.  3 versus 6 months of adjuvant oxaliplatinfluoropyrimidine combination therapy for colorectal cancer: an international, randomised, phase 3, non-inferiority trial.  Lancet Oncol. 2018 Apr;19(4):562-578.

TACTIC

Ferraro D, Goldstein D, O’Connell RL, Zalcberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, Gebski VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. Cancer Chemotherapy and Pharmacology 2016; 78(2): 361–367.
TOPGEAR

Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O’Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology. Published online 25 Mar 2017.

Leong T, Smithers BM, Michael M, Gebski V, Boussoutias A, Miller D, Simes J, Zalcberg J, Hausterman K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer 2015; 15: 532.

TROG 01.04

McLachlan SA, Fisher RJ, Zalcberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland SP, McKendrick J, McClure B, Mackay J, Ngan SY. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). European Journal of Cancer 2016; 55: 15–26.

Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartopeanu C, Zalcberg J, Mackay J. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. Journal of Clinical Oncology 2012; 30(31): 3827–3833.


Conference presentations

A La Cart

Warwick AM, Bernardi MP, Davies L, Stevenson ARL. Comparing three modes of rectal dissection for cancer: open vs laparoscopic vs transanal total mesorectal excision. European Society of Coloproctology 11th Congress; 28–30 Sep 2016; Milan.

Stevenson A, Solomon P, Hewett J, Lumley A, Hague W, Gebski V, Wilson K, Simes J. A La CaRT: Australasian laparoscopic cancer of the rectum trial. A phase III randomised trial comparing laparoscopic-assisted resection versus open resection for rectal cancer. Tripartite Colorectal Meeting; 30 Jun–3 Jul 2014; Birmingham.

Stevenson A, Hewett P, Lumley J, Clouston A, Simes J, Hague W, Gebski V, Quiene S, Wilson K, Solomon M. A La CaRT: Australasian Laparoscopic Cancer of the Rectum Trial: a phase III prospective randomised trial comparing laparoscopic-assisted resection versus open resection for rectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

ABC

1. Australasian Gastrointestinal Trials Group; Shannon JA, Goldstein D, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Jones-Murphy M. A phase II trial of gemcitabine in fixed dose rate infusion combined with low dose cisplatin in patients with inoperable biliary tract carcinomas. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 243.
2. Goldstein D, Shannon J, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Adams K; for the Australasian Gastro-Intestinal Trials Group. ABC: an AGITG trial of fixed dose rate gemcitabine and cisplatin for patients with advanced biliary tract cancer. 43rd Annual Scientific Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S, Part 1): 15015.
AG0001H

Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Dickman B, Gebski V. Somatostatin receptor expression and clinical effects of octreotide in patients with advanced hepatocellular carcinoma. Clinical Oncological Society of Australia 30th Annual Scientific Meeting; 25–28 Nov 2003; Perth.

Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Dickman B, Gebski V. Somatostatin receptor expression and clinical effects of Sandostatin LAR in patients with advanced hepatocellular carcinoma. American Society of Clinical Oncology; 31 May–3 June 2003; Chicago.

AG9401

Ackland S, Moore M, Jones M, Tu D, Simes R, Yuen J, Sargeant A, Dhillon H, Goldberg R, Abdi E, Shepherd L A. Meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting; 12–15 May 2001; San Francisco.
AG9601

Cullingford G, Findlay M, Storey D, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Gebski V, Dhillon H. A phase II feasibility study of preoperative and postoperative chemotherapy (epirubicin, cisplatin and 4FU) in patients with advanced but operable gastric cancer. American Society of Clinical Oncology Annual Scientific Meeting; 18–21 May 2002; Orlando.
AG9801

Ackland SP, Moore M, Jones M, Tu D, Simes RJ, Yuen J, Sargeant A, Dhillon H, Goldberg R, Abdi E, Shepherd LA. Meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Clinical Oncological Society of Australia; 28-30 November 2001; Brisbane.

Findlay M, Ackland S, Gebski V, Yuen J, Boyer M, Walpole E, Wilcken N, Zalcberg J, for the Australasian Gastro-Intestinal Trials Group. Phase II study of irinotecan, leucovorin and 5-fluorouracil in advanced gastric cancer. Clinical Oncological Society of Australia; 28–30 Nov 2001; Brisbane.

Findlay M, Ackland S, Gebski V, Yuen J, Boyer M, Walpole E, Wilcken N, Zalcberg J, Australasian Gastrointestinal Trials Group (AGITG). Phase II study of irinotecan, leucovorin and 5-fluorouracil in advanced gastric cancer. American Society of Clinical Oncology Annual Meeting; 12–15 May 2001; San Francisco.

AG9802

Gray B, Van Hazel G, Anderson J, Price D, Moroz P, Bower G, Blackwell A, Gebski V. Randomised phase II trial of SIR-Spheres plus flourouracil/leucovorin chemotherapy versus flourouracil/leucovorin chemotherapy alone on advanced colorectal hepatic metastases. American Society of Clinical Oncology Annual Scientific Meeting; 18–21 May 2002; Orlando.
ARCAD

Burzykowski T, Coart E, Saad ED, Sargent D, Zalcberg J, Shi Q, Sommeijer DW, Buyse ME. Tumor-size-based endpoints as surrogates for overall survival in the ARCAD advanced colorectal cancer database. Gastrointestinal Cancers Symposium; 19–21 Jan 2017; San Francisco.

Franko J, Shi Q, Meyers JP, Heinemann V, Falcone A, Tebbutt NC, Maughan T, Seymour M, Saltz L, Tournigand C, Diaz-Rubio E, Sougklakos I, Chibaudel B, Moen J, De Gramont A, Adams RA, Sargent DJ, Grothey A. Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer patients treated by systemic chemotherapy: findings from 9,265 patients in the ARCAD database. Gastrointestinal Cancers Symposium; 21–23 Jan 2016; San Francisco.

Sjoquist KM, Bokemeyer C, Renfro LA, Simes J, Tebbutt NC, S.J. C, Adams R, Punt CJA, Cutsem EV, Douillard JY, Hecht R, Heinemann V, Sougklakos I, Diaz-Rubio E, Porschen R, Meyers JP, Gonsalves WI, Sargent DJ, De Gramont A, Zalcberg J. Calculators for overall survival and progression-free survival in metastatic colorectal cancer: construction from 19,678 ARCAD patients. American Society of Clinical Oncology Annual Meeting; 29 May−2 Jun 2015; Chicago.

Sjoquist KM, Renfro LA, Simes J, Tebbutt NC, Clarke SJ, Meyers JP, Gonsalves WI, Adams R, Seymour MT, Saltz L, Schmoll H, Sargent DJ, De Gramont A, Zalcberg JR, on behalf of the Fondation Aide et Recherche en Cancérologie Digestive (ARCAD) Group. Nomograms for overall survival and progression-free survival in metastatic colorectal cancer: construction from 19,678 ARCAD patients. Gastrointestinal Cancers Symposium; 15–17 Jan 2015; San Francisco.

Saad ED, Coart E, Sommeijer DW, Shi Q, Zalcberg JR, Burzykowski T, Meyers JP, Hoff PM, Hecht R, Hurwitz H, Tol J, Tebbutt NC, Fuchs CS, Diaz-Robio E, Souglakos J, Falcone A, Kabbinavar FF, Sargent DJ, De Gramont A, Buyse ME, for the ARCAD Group. Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer: analysis of individual patient data from the ARCAD database. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Sommeijer DW, Shi Q, Saad ED, Coart E, Buyse ME, Burzykowski T, Meyers JP, Maughan T, Adams RA, Seymour MT, Saltz L, Goldberg RM, Douillard JY, Schmoll HJ, Punt CJA, Tournigand C, Chibaudel B, De Gramont A, Sargent DJ, Zalcberg JR, Group For the ARCAD. Early predictors of prolonged overall survival in patients (pts) on first-line chemotherapy for metastatic colorectal cancer: n ARCAD study with individual patient data on 10,962 patients. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Vernerey D, Hammel P, Paget-Bailly S, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, Moore M, André T, Mineur L, Chibaudel B, Louvet C, Bonnetain F. Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Sommeijer D, Shi Q, Meyers J, Sjoquist K, Hoff P, Seymour M, Cassidy J, Goldberg R, Douillard J, Hecht J, Hurwitz H, Tournigand C, Tebbutt N, Aranda E, Souglakos J, Kabbinavar F, Chibaudel B, De Gramont A, Sargent D, Zalcberg J, for the ARCAD Group. Prognostic value of early objective tumor response to first-line systemic therapy in metastatic colorectal cancer: individual patient data meta-analysis of randomized trials from the ARCAD database. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 3520.

ARCTIC

Price T, Wilson K, Simes J, Yip D, Tebbutt N, Karapetis C, Gebski V, Fournier M, Ferry D, Ransom D. Final results of Australasian Gastro-Intestinal Trials Group (AGITG) ARCTIC study—an international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. European Society for Medical Oncology (ESMO) Congress; 28 Sep–2 Oct 2012; Vienna.

Ransom D, Wilson K, Bishnoi S, Simes J, Yip D, Karapetis C, Gebski V, Gordon S, Fournier M, Ferry D, Abbas H, Midgley R, Price T. Results of Australasian Gastrointestinal Trials Group (AGITG) Arctic study: An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.

Bishnoi S, Ransom D, Stone C, Gordon S, Simes J, Wilson K, Townsend A, Price T. ARCTIC pilot study: audit of raltitrexed for patients with cardiac toxicity induced by capecitabine/5 fluorouracil. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

ASCOLT

Segelov E, Zielinski R, Asghari R, Simes J, Yip S, Coote A, Friend C, Aiken C, Kuang JCW, Jeffery M. ASCOLT: Aspirin for Dukes C and high risk Dukes B colorectal cancers. Clinical Oncological Society of Australia 43rd Annual Scientific Meeting; 15–17 Nov 2016; Gold Coast.
ATTACHE

Goldstein D, Fawcett J, Bridgewater J, Choti M, Wilson K, Gebski V, Aiken C, Eminton Z, Falk S, Stanton L, Primrose J. Safety and toxicity of peri‐operative and post‐operative adjuvant therapy for hepatic metastases from colorectal cancer: results from AGITG ATTACHE, CRUK EPOC‐B and NSABP C‐11. European Cancer Congress 2015; 25-29 Sep 2015; Vienna.

Fawcett J, Sjoquist K, Padbury R, Christophi C, Tebbutt N, Pilgrim C, Gebski V, Aiken C, Wong N, Goldstein D. ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.

Sjoquist K, Goldstein D, Fawcett J, Padbury R, Christophi C, Tebbutt N, Gebski V, Wong N, Aiken C. ATTACHE: a trial in the timing of surgery and adjuvant chemotherapy for hepatic metastases from colorectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 184. Abstract 295.

ATTAX

Tebbutt NC, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Gebski V, Munro S, Cummins M; on behalf of the Australasian GI Trials Group. ATTAX: randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5-FU or capecitabine in metastatic oesophago-gastric cancer: final results of an AGITG trial. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago.

Tebbutt N, Gebski V, Strickland A, Gibbs D, Walpole E, Ganju V, Goldstein D, Munro S, Harrod M, Van Hazel G, Australasian Gastro-Intestinal Trials Group. Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. 42nd Annual Meeting of the American Society of Clinical Oncology; 2–6 Jun 2006; Atlanta. Journal Of Clinical Oncology 2006; 24 (18): 194S. 4067.

ATTAX 2

Tebbutt NC, Sourjina T, Strickland AH, Van Hazel G, Pavlakis N, Ganju V, Murone C, MacGregor D, Gebski V, Cummins M. ATTAX2—docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 87.

Tebbutt NC, Sourjina T, Strickland AH, Van Hazel G, Pavlakis N, Ganju V, Murone C, MacGregor D, Gebski V, Cummins M. ATTAX2—docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 15554.

ATTAX 3

Tebbutt NC, Gebski VJ, Hall M, Wong N, Veillard AS, Wilcken N, Price TJ. Randomised, phase II study of weekly docetaxel, cisplatin and 5-fluorouracil or capecitabine given with or without panitumumab in advanced oesophago-gastric cancer: the AGITG ATTAX 3 trial. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

Tebbutt N, Price T, Sjoquist K, Veillard A, Hall M, Ferraro D, Wong N, Pavlakis M, Strickland A, Varma S, Cooray P, Young R, Underhill C, Shannon J, Ganju V, Gebski V, Group. AGT. Final results of AGITG ATTAX3 study: randomized phase II study of weekly docetaxel, cisplatin, and fluoropyrimidine with or without panitumumab in advanced esophagogastric cancer. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 4081.

C07

Marks P, Dhillon H, Simes J, for the Australasian Gastro-Intestinal Trials Group and NHMRC Clinical Trials Centre. Screening logs for improving recruitment to the NSABP C-07 trial. Clinical Oncological Society of Australia Annual Scientific Meeting; 28-30 November 2001; Brisbane.

O’Connell M, Lee M, Lopatin M, Yothers G, Clark-Langone K, Millward C, Pail S, Sharif S, Shak S, Wolmark N. Validation of the 12-gene colon cancer recurrence score in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV and 5FU/LV+oxaliplatin. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract 3512 .

CO.17

Sud S, O’Callaghan CJ, Jonker C, Karapetis CS, Price TJ, Tebbutt NC, Shapiro JD, Van Hazel GA, Pavlakis N, Gibbs P, Jeffery M, Siu LL, Gill S, Wong R, Jonker DJ, Tu D, Goodwin RA. Hypertension as a predictor of outcome and treatment response to cetuximab: a retrospective analysis of NCIC CTG CO.17. Gastrointestinal Cancers Symposium; 21–23 Jan 2016; San Francisco.

Sud S, O’Callaghan CJ, Karapetis CS, Jonker C, Price TJ, Tebbutt NC, Shapiro J, Van Hazel GA, Pavlakis N, Gibbs P, Jeffery M, Siu LL, Gill S, Wong R, Jonker DJ, Tu D, Goodwin RA. Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: aretrospective analysis of NCIC CTG CO.17. American Society of Clinical Oncology Annual Meeting; 3–7 Jun 2016; Chicago.

Brulé S, Jonker D, Karapetis C, O’Callaghan C, Moore M, Wong R, Tebbutt N, Underhill C, Yip D, Zalcberg J, Tu D, Goodwin R. Location of colon cancer (right-sided versus left-sided) as a predictor of benefit from cetuximab in NCIC CTG CO.17. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31(suppl.): 3528.

Jonker D, Karapetis C, O’Callaghan C, Marginean C, Zalcberg J, Simes J, Moore M, Tebbutt N, Price T, Daneshmand M, Hanson J, Shapiro J, Pavlakis M, Gibbs P, Van Hazel G, Lee U, Haq R, Virk S, Tu D, Lorimer I, NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. BRAF, PIK3CA, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer: results from NCIC CTG/AGITG CO.17. American Society of Clinical Oncology; 1–5 May Chicago. Abstract 3515.

Elimova E, O Callaghan CJ, Tu D, Karapetis CS, Price TJ, Zhu L, Zalcberg JR, Simes J, Jonker DJ. Cetuximab related hypersensitivity reactions: An analysis of timing, demographics, and outcomes from the AGITG / NCIC CTG CO.17 trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

O’Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Tebbutt NC, Trudeau MG, Price TJ, Yip D, Jonker DJ. The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Van Hazel GA, Tu D, Tebbutt C, Jonker DJ, Price TJ, O’Callaghan C, Zalcberg JR, Simes J, Yip D, Jefford M, Strickland AH, Burnell MJ, Karapetis CS. Early change in tumor size from waterfall plot analysis and RESIST response as predictor of overall survival in advanced, chemotherapy-refractory colorectal cancer: NCIC CTG/AGITG CO.17 study. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Vickers MM, Karapetis C, Tu D, Zalcberg J, O’Callaghan C, Simes J, Moore M, Zhu L, Jonker DJ. The influence of hypomagnesemia on overall survival in a phase III randomized study of cetuximab plus best supportive care (BSC) versus BSC: NCIC CTG / AGITG CO.17. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Jonker D, Karapetis C, Harbison C, O’Callaghan C, Tu D, Simes J, Xu LA, Moore M, Zalcberg J, Khambata-ford S. High epiregulin gene expression plus KRAS wild-type status predict for cetuximab benefit in the treatment of advanced colorectal cancer: results from NCIC CTG CO.17: a phase III trial of cetuximab vs best supportive care. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando.

Powell ED, Asmis T, Jonker D, Tu C, Karapetis C, Jeffery M, O’Callaghan C. Comorbidity and overall survival in cetuximab-treated patients with advanced colorectal cancer—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4074.

Karapetis C, Khambata-Ford S, Jonker D, O’Callaghan C, Tu D, Vachan B, Simes J, Langer C, Moore M, Zalcberg J. K-ras mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer — results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. 33rd Congress of the European Society of Medical Oncology; 12–16 Sep 2008; Stockholm. Annals of Oncology 2008; 19: viii2. Abstract LBA6.

Mittmann N, Au HJ, Tu D, O’Callaghan CJ, Karapetis CS, Moore MJ, Zalcberg J, Simes J, Evans WK, Jonker DJ. A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 6528.

O’Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Zalcberg JR, Trudeau M, Yip D, Vachan B, Jonker DJ. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC–CTC CO.17. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 4130.

Au H, Karapetis C, Jonker D, O’Callaghan C, Kennecke H, Shapiro J, Tu D, Wierzbicki R, Zalcberg J, Moore M. Quality of life in patients with advanced colorectal cancer treated with cetuximab: results of the NCIC CTG and AGITG CO.17 trial. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S, Part 1): 4002.

Jonker DJ, Karapetis CS Moore MJ, Zalcberg JR, Tu D, Au H, Berry S, Krahn M, Simes RJ, Tebbutt N, van Hazel G, O’Callaghan CJ. A phase III randomized study of cetuximab (Erbitux, C225) and best supportive care versus best supportive care in patients with pretreated metastatic colorectal carcinoma. American Association for Cancer Research Annual Meeting; 14–18 Apr 2007; Los Angeles.

Diakos CI, Tu D, Gebski V, Yip S, Wilson K, Karapetis C, O’Callaghan CJ, Shapiro J, Tebbutt N, Jonker DJ, Sui LL, Wong R, Doyle C, Strickland AH, Price TJ, Simes J, Clarke S. Is the derived neutrophil to lymphocyte ratio an independent prognostic marker in patients with metastatic colorectal cancer? Analysis of the CO.17 and CO.20 studies. European Society for Medical Oncology 41st Congress; 7–11 Oct 2016 2016; Copenhagen.

CO.20

Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O’Callaghan C, Jonker D, J., Tu D, Chen E, Morgen E, Price TJ, Shapiro JD, Siu LL, Owzar K, Ratain MJ, Kubo M, Dubrovic A, Xu W, Mushiroda T, Liu G. The association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 18–20 Jan 2018; San Francisco.

Diakos CI, Tu D, Gebski V, Yip S, Wilson K, Karapetis C, O’Callaghan CJ, Shapiro J, Tebbutt N, Jonker DJ, Sui LL, Wong R, Doyle C, Strickland AH, Price TJ, Simes J, Clarke S. Is the derived neutrophil to lymphocyte ratio an independent prognostic marker in patients with metastatic colorectal cancer? Analysis of the CO.17 and CO.20 studies. European Society for Medical Oncology 41st Congress; 7–11 Oct 2016 2016; Copenhagen.

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland AH, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan SS, Easaw JC, Shannon JA, El-Tahche F, Walters IB, Tu D, O’Callaghan CJ; the NCIC-CTG and the AGITG. Quality of life assessment in patients with K-RAS wild-type chemotherapy refractory metastatic colorectal cancer treated with cetuximab plus brivanib alaninate. ASCO Gastrointestinal Cancers Symposium; 19–21 Jan 2012; San Francisco.

Shapiro JD, Siu LL, O’Callaghan CJ, Zalcberg JR, Moore MJ, Price TJ, Doyle C, Simes J, Findlay P, Cronk MF, Shaikh A, Joubert WL, Samson B, Bonaventura A, Underhill C, Wyld D, Walters IB, Phillips P, Tu D, Jonker DJ; NCIC CTG AND AGITG. Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: a phase III randomized trial of cetuximab plus either brivanib alaninate or placebo in patients with chemotherapy refractory, k-RAS wild-type metastatic colorectal carcinoma. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract 3572.

Siu L, Shapiro J, Jonker D, Karapetis C, Zalcberg J, Simes J, Couture F, Moore M, Price T, Siddiqui J, Nott L, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski N, Haydon A, Walters I, Tu D, O’Callaghan C, NCIC Clinical Trials Group and, AGITG. Final analysis of the phase III randomized trial of cetuximab plus either brivanib alaninate or placebo in patients with metastatic chemotherapy refractory K-RAS wild-type colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract 3504

Siu LL, Shapiro JD, Jonker Dj, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw WS, Sawyer MB, Jefford M, Magoski NM, Haydon AM, Walters IB, Tu D, O’Callaghan CJ; NCIC Clinical Trials Group and AGITG. Phase III randomized trial of cetuximab plus either brivanib alaninate or placebo in patients with metastatic chemotherapy refractory K-RAS wild-type colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. ASCO Gastrointestinal Cancers Symposium; 19–21 Jan 2012; San Francisco.

Shapiro J, Siu LL, Zalcberg J, Moore M, Ringash J, Mittmann N, Simes J, O’Callaghan CJ, Tu D, Walters I, Magoski N, Smith P, Nomikos D, Zhu L, Savoie M, Virk S, El-Tahche F, Gill R, Price T, Jonker D. A phase III study of cetuximab plus either brivanib alaninate versus placebo in patients with chemotherapy-refractory KRAS wild-type advanced colorectal cancer. The NCIC CTG/AGITG CO.20 trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

CO.23

Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei A, Gao Y, Tebbutt N, Markman B, Esaki T, Koski S, Hitron M, Magoski NM, Simes J, Li C, Tu D, O’Callaghan CJ. A randomized phase III study of napabucasin [BBI608] vs placebo in patients with pretreated advanced colorectal cancer: the CCTG/AGITG CO.23 trial. European Society for Medical Oncology 41st Congress; 7–11 Oct 2016 2016; Copenhagen.

Jonker DJ, Nott LM, Yoshino T, Li C, Gill S, Shapiro JD, Ohtsu A, Zalcberg JR, Vickers MM, Simes J, Wei AC, Mittmann N, Magoski NM, Murray Y, Tsobanis E, Tu D, Kerstein D, O’Callaghan CJ. NCIC CTG and AGITG CO.23 trial: a phase III randomized study of BBI608 plus best supportive care versus placebo plus best supportive care in patients with pretreated advanced colorectal carcinoma. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Da Vinci

Clarke SJ, Brown C, Simes J, Van Hazel G, Jeffery M, Tebbutt N, Ransom D, Buck M, Boland A, Zalcberg J; Australasian Gastro-Intestinal Trials Group. AGITG DaVINCI Trial: Randomised phase II trial of De Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan in patients with previously treated metastatic colorectal cancer. Gastrointestinal Cancers Symposium; 15–17 Jan 2009; San Francisco.

Brown C, Hudson M, Yip S, Clarke S, Gebski V. Incorporating historical control estimates into meta-analyses. Australian Statistical Conference; 9–12 Jul 2012; Adelaide.

DOCTOR

Barbour A, Walpole E, Mai GT, Chan H, Barnes E, Watson D, Ackland S, Wills V, Martin J, Burge M, Karapetis C, Shannon J, Nott L, Gebski V, Wilson K, Thomas J, Lampe G, Zalcberg J, Simes J, Smithers M. An AGITG trial: a randomised phase II study of pre-operative cisplatin, fluorouracil and docetaxel ± radiotherapy based on poor early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma. European Society for Medical Oncology 41st Congress; 7–11 Oct 2016 2016; Copenhagen.

Barbour A, Smithers BM, Burmeister B, Zalcberg JR, Spry N, Smith G, Wilson K, Roff K, Yip S, Walpole ET; Australasian Gastro-Intestinal Trials Groups (AGITG). DOCTOR: a randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract TPS4145.

EORTC 40983

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P, Bechstein W, Primrose J, Walpole E, Mauer M, Gruenberger T, for the EORTC GI Group, CR UK, ALMCAO, AGITG, Nordic Group, and FFCD. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. American Society of Clinical Oncology; 1–5 Jun 2012; Chicago.

Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston G, Schlag P, Rougier P, Primrose J, Walpole E, Nordlinger B. Evaluation of carcinoembryonic antigen as a predictive baseline factor for the benefit of perioperative FOLFOX in resectable liver metastasis from colorectal cancer (EORTC study 40983). Gastrointestinal Cancers Symposium 2010.

Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston G, Schlag P, Rougier P, Primrose J, Walpole E, Nordlinger B. Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). American Society of Clinical Oncology Annual Meeting; 12-15 May 2010; San Francisco. Journal of Clinical Oncology 2010; 28(15S). Abstract 3544.

Julié C, Lutz MP, Aust D, Kandutsch S, Collette L, Praet M, Gruenberger T, Van Cutsem E, Nordlinger B. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. Gastrointestinal Cancers Symposium; 19–21 Jan 2007; Orlando. Abstract 241

Nordlinger B, Sorbye H, Collette L, Praet M, Glimelius B, Poston G, Schlag P, Rougier P, Bechstein W, Primrose J, Walpole E, Finch-Jones M, Jaeck D, Mirza D, Parks R, Gruenberger T.. Survival after peri-operative chemotherapy with Folfox 4 and surgery for resectable colorectal cancer liver metastases. Final results of the EORTC Intergroup randomized phase III study 40983. World Congress on Gastrointestinal Cancer; 28 Jun–1 Jul 2007; Barcelona. Annals of Oncology 2007; 18(suppl.7): vii20.

Nordlinger B, Sorbye H, Collette L, Glimelius B, Poston G, Schlag P, Rougier P, Bechstein W, Walpole E, Gruenberger T. Final results of the EORTC Intergroup randomized phase III study 40983 (EPOC) evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. 43rd Annual Meeting of the American Society of Clinical Oncology; 1-5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S). Abstract LBA5.

Gruenberger T, Sorbye H, Debois M, Bethe U, Primrose J, Rougier P, Jaeck D, Finch-Jones M, Van Cutsem E, Nordlinger B, EORTC GI group. Tumor response to preoperative chemotherapy with Folfox-4 for resectable colorectal cancer liver metastases. Interim results of EORTC Intergroup randomized phase III study 40983. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2006; Chicago. Journal of Clinical Oncology 2007; 24 (18S, Part I): 3500.

Nordlinger B, Sorbye H, Debois M, Praet M, Glimelius B, Poston G, Schlag P, Walpole E, Bechstein W, Gruenberger T. Feasibility and risks of pre-operative chemotherapy with FOLFOX 4 and surgery for resectable colorectal cancer liver metastases. Interim results of the EORTC Intergroup randomized phase III study 40983. 42nd Annual Meeting of the American Society of Clinical Oncology; 2-6 Jun 2005; Atlanta. Journal of Clinical Oncology 2005; 23(16S): 3528.

Walpole E, McCall J, Fawcett J, Zalcberg J, Schroeder J, Dhillon H, for the Australasian Gastro-Intestinal Trials Group. Randomised study of perioperative chemotherapy with infusional fluorouracil/leucovorin and oxaliplatin for liver metastases of colorectal cancer. Clinical Oncological Society of Australia Annual Scientific Meeting; 28-30 November 2001; Brisbane.

EORTC 62005

Hohenberger P, Bonvalot S, Litiere S, Rutkowski P, van Coevorden F, Meeus P, Marréaud S, Raventos VA, Kotasek D, Padbury R, Van der Graaf W, Gronchi A. Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross-match comparison in the EORTC intergroup study 62005, aimed at assessing the clinical activity of imatinib at two dose levels in patients with unresectable or metastatic GIST Connective Tissue Oncology Society; 15–18 Oct 2014; Berlin.

Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner L, Judson I, Fumagalli E, Hogendoorn P, Natukunda A, Marreaud S, Litiere S, van Der Graaf WTA. Long-term analysis of a phase III randomized, intergroup, international trial assessing the clinical activity of imatinib at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors. Connective Tissue Oncology Society 18th Annual Meeting; 30 Oct–2 Nov 2013; New York.

Lee CK, Joensuu H, McArthur G, Montemurro M, Yip D, Goldstein D, Bylina E, Andrzejuk J, Siedlecki JA, Rutkowski P. Development and validation of prognostic nomograms to predict survival outcomes in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first line imatinib therapy. Connective Tissue Oncology Society 18th Annual Meeting; 30 Oct–2 Nov 2013; New York.

Goldstein D, Lee C, Tracey E, Cook-Yarborough C, Lord S. Validating innovation: a population-based study of gastrointestinal stromal tumors (GIST) to estimate the survival benefit of imatinib. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Van Glabbeke MM, Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichardt P, Issels R, Judson I, Debiec-Rychter, Blay J. Type of progression in patients treated with imatinib for advanced gastrointestinal stromal tumor: a study based on the EORTC-ISG-AGITG trial 62005. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 10536.

Romeo S, Van Paassen H, Van Glabbeke M, Comitel P, Oosting J, Nielsen OS, Verweij J, Sciot R, Debiec-Rychter M, Hogendoorn PCW. Pattern of expression of cell cycle/apoptosis regulators reflect location, mutation and progression free survival (PFS) of gastrointestinal stromal tumour (GIST) treated with imatinib from randomized phase III trial 62005 EORTC/STBSG. European Society of Pathology Annual Congress; 8-13 Sep 2007; Istanbul. Virchows Archive 2007; 451(2): 151.

Le Cesne A, Van Glabbeke M, Verweij J, Casali P, Zalcberg J, Reichardt P, Issels RD, Judson IR, Blay JY. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate included in the intergroup EORTC/ISG/AGITG trial? 42nd Annual Meeting of the American Society of Clinical Oncology 2–6 Jun 2006; Atlanta. Journal of Clinical Oncology 2006; 24 (18S, Part 1): 9510.

Casali PG, Verweij J, Kotasek D, LeCesne A, Reichardt P, Blay JY, Issels R, Rychter MD, Van Glabbeke M, Judson I. Imatinib mesylate in advanced gastrointestinal stromal tumors: survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. EJC Supplements 2005; 3(2): 201–202.

Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR. Outcome of patients with advanced gastro-intestinal stromal tumors crossing over to a daily imatinib dose of 800 mg after progression on 400mg: an international, intergroup study of the EORTC, ISG and AGITG. 40th Annual Meeting of the American Society of Clinical Oncology; 5–8 Jun 2004; New Orleans. Journal of Clinical Oncology 2004; 22(14): 819S.

Van Glabbeke M, Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichard P, Blay J, Schlemmer M, Donato Di Paola E, Judson I. Prognostic factors of toxicity and efficacy in patients with gastro-intestinal stromal tumors (GIST) treated with imatinib: a study of the EORTC-STBSG, ISG and AGITG. American Society of Clinical Oncology; 31 May–3 Jun 2003; Chicago.

Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichard P, Blay J, Issels R, Van Glabbeke M, Donato Di Paola E, Judson I. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors: Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. American Society of Clinical Oncology; 31 May–3 Jun 2003; Chicago.

Zalcberg J, Verweij J, Casali P, Le Cesne A, Reichardt P, Blay J, Issels R, Van Glabbeke M, Donato di Paola E, Judson I, Dhillon H, Kotasek D, Findlay M, Goldstein D. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors: interim results of a randomized phase II trial from EORTC-STBSG, ISG & AGITG. Clinical Oncological Society of Australia 30th Annual Scientific Meeting; 25–28 Nov 2003; Perth.

Casali PG, Verweij J, Zalcberg J, Le Cesne A, Reichardt P, Ray-Coquard I, Wendtner C, Judson I, Di Paola ED, Van Glabbeke M, Bertulli R, Dhillon H, Nielsen OS. Imatinib (Glivec) 400 vs 800 mg daily in patients with gastrointestinal stromal tumors: a randomized phase III trial from the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group (ISG), and the Australasian Gastro-Intestinal Trials Group (AGITG). A toxicity report. American Society of Clinical Oncology Annual Meeting; 18–21 May 2002; Orlando.

EORTC 62024

Casali P, LeCesne A, Valasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson I, Italiano A, Broto J, Gronchi A, Dei Tos A, Marreaud S, Van Der Graaf W, Zalcberg J, Litière S, Blay J, EORTC Soft Tissue and Bone Sarcoma Group (EORTC STBSG), French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Grupo Español de Investigación en Sarcomas (GEIS), Australasian Gastro-Intestinal Trials Group (AGITG). Imatinib failure-free survival in patients with localized gastrointestinal stromal tumors treated with adjuvant imatinib: the EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 10500.

Hohenberger P, Rutkowski P, Bonvalot S, van Coevorden F, Stoeckle E, Olungu C, Ouali M, Casali P, Gronchi A. Analysis of the quality of reporting surgical procedures in patients undergoing resection for primary gastrointestinal stromal tumors: a reporting tool derived from the EORTC–STBSG 62024 trial. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago.

Van Glabbeke MM. Owzar K, Rankin C, Simes J, Crowley J; GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analyis based on 1640 patients. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S, Part 1): 10004.

ESPAC 3

Neoptolemos J, Greenhalf W, Ghaneh P, Palmer D, Cox T, Garner E, Campbell F, Mackey J, Moore M, Valle J, Mcdonald A, Tebbutt N, Darvenos C, Glimelius B, Charnley R, Lacaine F, Mayerle J, Rawcliffe L, Bassi C, Buchler M, European Study Group for Pancreatic Cancer. HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago.

Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald A, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Coxon FY, Lacaine F, Middleton R, Ghaneh P, Bassi C, Halloran C, Olah A, Rawcliffe CL, Büchler MW, European Study Group for Pancreatic Cancer. Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago. Journal of Clinical Oncology 2011; 29 (suppl.). Abstract LBA4006.

Neoptolemos J, Büchler M, Stocken DD, Ghaneh P, Smith D, Bassi C, Moore M, Cunningham D, Dervenis C, Goldstein D. ESPAC-3(v2): a multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 18s. Abstract LBA4505.

Padbury R, Goldstein D, Knight E, Dhillon H, Tebbutt N, Yip S, Simes J. Continuation of an adjuvant therapy trial in the light of new evidence: revised design of the European Study Group for Pancreatic Cancer 3 trial (ESPAC-3). Clinical Oncological Society of Australia 30th Annual Scientific Meeting; 25–28 Nov 2003; Perth.

GAP

Barbour A, O’Rourke N, Chan H, Chua YJ, Kench J, Hicks RJ, Samra JS, Pavlakis N, Haghighi KS, Yip S, Donoghoe M, Friend C, Burge Me, Fawcett J, Harris M, Aghmesheh M, Joubert WL, Gebski V, Simes J, Goldstein D. Initial survival outcomes for the AGITG GAP study: a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma. American Society of Clinical Oncology Annual Meeting; 3–7 Jun 2016; Chicago.

Barbour A, O’Rourke N, Chandrasegaram MD, Chua YJ, Kench J, Samra JS, Pavlakis N, Haghighi KS, Yip S, Fawcett J, Donoghoe M, Walker K, Burge ME, Gananadha S, Harris M, Aghmesheh M, Joubert WL, Gebski V, Simes J, Goldstein D. A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: the AGITG GAP study. American Society of Clinical Oncology Annual Meeting; 29 May−2 Jun 2015; Chicago.

Barbour A, O’Rourke N, Samra JS, Haghighi KS, Kench J, Mitchell J, Pavlakis N, Burge ME, Fawcett J, Gananadha S, Harris M, Aghmesheh M, Chua YJ, Joubert WL, Chan MMK, Chandrasegaram MD, Yip S, Simes J, Gebski V, Goldstein D. A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: the AGITG GAP study. Gastrointestinal Cancers Symposium; 15–17 Jan 2015; San Francisco.

Gofurtgo

Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTGO trial: an AGITG multicentre phase II study of fixed-dose-rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of locally advanced pancreatic cancer. Asian Oncology Summit; 9–11 Apr 2010; Nusa Dua, Bali.

Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTGO trial: an AGITG multicentre phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3D conformal radiotherapy for the treatment of locally advanced pancreatic cancer. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4616.

ICECREAM

Shapiro JD, Thavaneswaran S, Underhill C, Robledo KP, Karapetis CS, Day FL, Nott LM, M. J, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel G, Waring PM, Tejpar S, Simes J, Gebski V, Desai J, Segelov E. Results of the quad wild type arm of the AGITG ICECREAM study: a randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA. American Society of Oncology Annual Meeting; 2–6 Jun 2017; Chicago.

Segelov E, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlakis N, Nott L, Underhill C, Khasraw M, Wasan H, Ciardiello F, Jefford M, Joubert W, Haydon A, Karapetis C, Price T, Wilson K, Shapiro J. AGITG ICECREAM study: the Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation: analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. European Cancer Congress 2015; 25-29 Sep 2015; Vienna.

Segelov E, Wilson K, Gebski V, Waring P, Tabernero J, Wasan H, Ciardiello F, Desai J, Underhill C, Karapetis C, Khasraw M, Nott L, Joubert W, Pavlakis M, Van Hazel G, Chantrill L, Price T, Jefford M, Haydon A, Shapiro J. ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31(suppl.): TPS3649.

Segelov E, Wilson K, Gebski V, Waring P, Desai J, Nott L, Karapetis C, Hall M, Wasan H, Shapiro J. ICECREAM: irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. Clinical Oncological Society of Australia 40th Annual Meeting; 12-14 Nov 2013; Adelaide. Asia-Pacific Journal of Clinical Oncology 2013; S3: 155.

IG0401

Fitzgerald L, Stockler M, Gebski V, Burmeister B. How do you feel? Baseline quality of life in oesophageal cancer. Clinical Oncological Society of Australia Annual Scientific Meeting; 24-26 Nov 1999; Melbourne.

Sjoquist K, Gebski V; on behalf of the Australasian Gastro-Intestinal Trials Group. Updated meta-analysis of survival benefits of neoadjuvant chemotherapy or chemo-radiotherapy followed by surgery in resectable oesophageal carcinoma. Australasian Gastro-Intestinal Trials Group 12th Annual Scientific Meeting; 1–3 Sep 2010; Adelaide.

Burmeister B, Smithers B, Gebski V, Fitzgerald L, Devitt P, Ackland S, Joseph D, Denham J. Pre-operative chemoradiation for oesophageal cancer: results of the Australasian study IG9401. International Conference on Radiation Research; 17–22 Aug 2003; Brisbane.

Smithers B, Burmeister B, Fitzgerald L, Gebski V, Denham J, Devitt P, Ackland S, Joseph D, Millar J, North J, Walpole E, Gotley D. A randomized controlled trial of surgery alone compared with chemoradiation and surgery: a focus on the surgical outcomes. 56th Annual Cancer Symposium of the Society of Surgical Oncology; 5–9 Mar 2003; Los Angeles.

Burmeister B, Fitzgerald L, Gebski V, Stockler M. The Australian randomised oesophageal cancer trial IG 9401: a report on the second analysis. Asia Pacific Cancer Conference; 12-15 Dec 1999; Chennai.

IDEA

Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the idea analysis, European Society for Medical Oncology; 8–12 Sep 2017; Madrid.

IMPACT

1. Chantrill LA, Nagrial A, Johns A, McKay S, Gill AJ, Pavlakis N, Grimison PS, Asghari G, Waddell N, Chou A, Chin VT, Sebastian LT, Verghis J, Yip S, Sjoquist KM, Simes J, Biankin A. Clinical utilization of targetable molecular results in pancreatic cancer: longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial. Gastrointestinal Cancers Symposium; 19–21 Jan 2017; San Francisco.
2. Sebastian L, Verghis J, Simes J, Lee C, Sjoquist K, Biankin A, Nagrial A, Johns A, Gebski V, Grimison P, Pavlakis N, Asghari R, Miller D, Yip S, Thomas D, Chantrill L. Practical lessons from a pilot study of personalized treatment in pancreatic cancer: the IMPaCT study experience. An intergroup trial of the AGITG/NHMRC CTC/APGI/Kinghorn Cancer Centre/Sydney Catalyst. ACTA (Australian Clinical Trials Alliance) Symposium; 7–10 Oct 2015; Sydney.
3. Chantrill L, Sjoquist K, Lee C, Nagrial A, Johns A, Chin V, Chang D, Zalcberg J, Yip S, Biankin A, Simes J, Miller D, Sebastian L. Individualised molecular pancreatic cancer therapy. A randomised, open label, phase II trial assessing standard first line treatment with gemcitabine or personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer to evaluate feasibility and impact on progression free survival. Australasian Gastrointestinal Trials Group Annual Scientific Meeting; 20-22 Aug 2014; Brisbane.
4. Chantrill L, Johns A, Nagrial A, Chin V, Chou A, Pinese M, Mead S, Gebski V, Sjoquist K, Lee C, Yip S, Miller D, Sebastian L, Asghari R, Harvey S, Pavlakis N, Mukhedkar S, Grimison P, Miller D, Pearson J, Waddell N, Grimmond S, Simes J, Biankin A. The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomised, open label phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer. American Association for Cancer Research-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference; 19–23 Oct 2013; Boston.
5. Nagrial A, Biankin A, Chantrill L, Johns A, Chin V, Gebski V, Sjoquist K, Lee C, Yip S, Miller D, Sebastian L, Pavlakis N, Mukhedkar S, Asghari R, Simes J. The IMPACT trial: Individualised Molecular Pancreatic Cancer Therapy. A randomised, open label, phase II trial assessing standard first line treatment with gemcitabine or personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer to evaluate feasibility and impact on progression free survival. Sydney Cancer Conference; 27–28 Sep 2012; Sydney.
INTEGRATE

Yip S, Harvie R, Martin AJ, Sjoquist KM, Tsobanis E, Kang YK, Bang YJ, Alcindor T, O’Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Strickland A, Zalcberg JR, Simes J, Goldstein D, Pavlakis N. Evaluation of circulating VEGF based biomarkers in INTEGRATE: a randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group (AGITG). Gastrointestinal Cancers Symposium; 21–23 Jan 2016; San Francisco.

Pavlakis N, Sjoquist K, Tsobanis E, Martin A, Kang Y, Bang Y, O’Callaghan C, Tebbutt N, Rha S, Lee J, Cho J, Lipton L, Burnell M, Alcindor T, Strickland A, Wong M, Kim J, Simes J, Zalcberg J, Goldstein D. INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group (AGITG): first results. Gastrointestinal Cancers Symposium; 15–17 Jan 2015; San Francisco.

Pavlakis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang YK, Bang YJ, O’Callaghan CJ, tebbutt NC, Rha SY, Cho JY, Lipton LR, Burnell MJ, Alcindor T, Strickland A, Kim JW, Yip S, SImes J, Zalcberg J, Goldstein D. INTEGRATE: a randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)—final overall and subgroup results. American Society of Clinical Oncology Annual Meeting; 29 May−2 Jun 2015; Chicago.

Pavlakis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang Y-K, Bang Y-J, O’Callaghan CJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Burnell MJ, Alcindor T, Strickland A, Kim JW, Yip S, Simes J, Zalcberg JR, Goldstein D. INTEGRATE: a randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group: final overall and subgroup results. ESMO 17th World Congress on Gastrointestinal Cancer; 1–4 Jul 2015; Barcelona.

Pavlakis M, Goldstein D, Sjoquist K, Martin A, Tsobanis E, Yip S, Shannon J, Burge M, Cronk M, Tebbutt N, Strickland A, Lipton L, Price T, Nott L, Harris D, Burnell M, Alcindor T, Bang Y, Kang Y, O’Callaghan C. INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group (AGITG). American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31(suppl.): TPS4157.

INTEGRATE II

Sjoquist KM, Pavlakis N, Martin AJ, Tsobanis E, Yip S, Bang YJ, Alcindor T, O’Callaghan CJ, Shitara K, Bekaii-Saab TS, Grothey A, Chen LT, Simes J, Zalcberg R, Goldstein D. Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer—an international study organized by the Australasian Gastrointestinal Trials Group. American Society of Oncology Annual Meeting; 2–6 Jun 2017; Chicago.
INTERAACT

Sclafani F, Adams RA, Eng C, Benson AB, Glynne-Jones R, Sebag-Montefiore D, Arnold D, Roy AC, Guren MG, Segelov E, Seymour MT, Bryant A, Peckitt C, Cunningham D, Bridgewater JA, Welch J, O’Dwyer PJ, Dupont E, McConnell A, Rao S. InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel in patients with inoperable locally recurrent or metastatic disease. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.
LAP07

Huguet F, Hammel P, Vernerey D, Goldstein D, Van Laethem JL, Glimelius B, Spry N, S Paget-Bailly, Bonnetain F, Louvet C. Impact of chemoradiotherapy on local control and time without treatment in patients with locally advanced pancreatic cancer included in the international phase III LAP 07 study. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Ricadot S, Hammel P, Chibaudel B, Goldstein D, Spry N, Van Laethem J, Van Houtte P, Glimelius B, Gubanski M, Huguet F. Dummy run in the phase III LAP07 pancreatic cancer trial: First evaluation of quality of radiation therapy planning. American Society for Radiation Oncology 54th Annual Meeting; 28–31 Oct 2014; San Francisco.

Hammel P, Huguet F, Van Laethem J, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C. Comparison of chemoradiotherapy and chemotherapy in patients with a locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31(suppl.): LBA4003.

Goldstein D, Spry N, Padbury R, Kneebone A, Barbour A, Biankin A, Harris D, Wong N, Roff K, Shannon J. LAP 07: Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

MAGIC

Storey D; Australian Management Committee. MAGIC-MRC randomised trial of pre- and post-operative chemotherapy for operable gastric cancer: Insights from the Australasian Gastro-Intestinal Trials Group feasibility study (AG9601). 27th Annual Scientific Meeting of the Clinical Oncological Society of Australia; 28 Nov–1 Dec 2000; Adelaide.
MAX

Diakos CI, Wilson K, Asher R, Gebski V, Yip D, van Hazel G, Robinson B, Broad A, Price TJ, Simes J, Tebbutt N, Clarke S. Is baseline neutrophil to lymphocyte ratio an independent prognostic biomarker for progression free survival and overall survival in etastatic colorectal cancer? Analysis of the AGITG MAX study. European Society for Medical Oncology 41st Congress; 7–11 Oct 2016 2016; Copenhagen.

Chionh FJM, Gebski V, Cheuh AC, Al-Obaidi SJ, Weickhardt AJ, Lee C, Williams DS, Murone C., Wilson K, Scott AM, Simes J, Price TJ, Mariadason JM, Tebbutt NC. Single nucleotide polymorphisms in vascular endothelial growth factor family genes as predictive or prognostic biomarkers in patients with metastatic colorectal cancer: analysis of the phase III MAX study. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Price TJ, Bruhn MA, Lee C, Hardingham JE, Townsend AR, Mann K, Simes J, Weickhardt A, Wrin JW, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine alone or in combination with bevacizumab with or without mitomycin C in advanced colorectal cancer. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Price TJ, Buizen L, Hardingham J, Lee CK, Townsend A, Bruhn M, Simes RJ, Wilson K, Gebski V, Tebbutt NC. Molecular subgroups from the AGITG MAX trial; right or left primary site of colorectal cancer and outcomes for metastatic colorectal cancer. European Society for Medical Oncology Congress; 26–30 Sep 2014; Madrid.

Price TJ, Townsend AR, Bruhn MA, Lee C, Wrin J, Shivasami A, Arentz G, Tebbutt NC, Cunningham D, Hardingham J. Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer. Gastrointestinal Cancers Symposium; 16–18 Jan 2014; San Francisco.

Roohullah A, Sjoquist K, Gebski V, Ng W, Chua W., Price T, Tebbutt N, Chantrill L. The efficacy and safety outcomes of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the AGITG MAX clinical trial and in non-trial patients in two cancer centres. Gastrointestinal Cancers Symposium; 16–18 Jan 2014; San Francisco.

Roohullah A, Wong H, Sjoquist K, Field K, Tran B, Shapiro J, McKendrick J, Yip D, Nott L, Gibbs P, Chantrill L. Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database. Gastrointestinal Cancers Symposium; 16–18 Jan 2014; San Francisco.

Waring PM, Desai J, Rudzki ZB, Wilson K, Gebski V, Nott LM, Karapetis CS, Khasraw M, Underhill C, Pavlakis N, Chantrill LA, Shapiro JD, Segelov E. Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation) trial in metastatic colorectal cancer. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Carter H, Zannino D, Simes J, Schofield D, Howard K, Zalcberg J, Price T, Tebbutt N. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. 9th World Congress on Health Economics; 7–10 Jul 2013; Sydney.

Price T, Hocking C, Broadbridge V, Wrin J, Townsend A, Tebbutt N, Cooper J, Ruszkiewicz A, Lee C, Hardingham J. Can we accurately report PTEN status in advanced colorectal cancer? European Cancer Congress; 27 Sep–1 Oct 2013; Amsterdam.

Weickhardt A, Nguyen T, Paskulin D, Le A, Aisner D, Schulte N, Chionh F, Mariadason J, Tebbutt N. ALK and ROS1 gene rearrangements detected in colorectal cancer by fluorescence in situ hybridization. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 3545.

Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D,Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: overall and subgroup analyses of pooled data from randomized controlled trials. ESMO 14th World Congress on Gastrointestinal Cancer; 27–30 Jun 2012; Barcelona. Annals of Oncology 2012; 23(suppl. 4): iv12-13. Abstract 0-0018.

Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from randomized controlled trials. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.

Price T, Hardingham J, Lee C, Wrin J, Townsend A, Wilson K, Weickhardt A, Simes J, Murone C, Tebbutt N. Analysis of PTEN in patients with advanced colorectal cancer receiving capecitabine alone or in combination with bevacizumab ± mitomycin C in the phase III AGITG MAX trial. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.

Price TJ, Hardingham J, Lee C, Wrin J, Townsend AR, Wilson K, Weickhardt AJ, Simes J, Murone C, Tebbutt NC. PTEN and advanced colorectal cancer: analysis from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab +/- mitomycin C. European Society for Medical Oncology (ESMO) Congress; 28 Sep–2 Oct 2012; Vienna.

Tebbutt N, Hurwitz H, Kabbinavar F, Giantonio B, Guan Z, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from randomized controlled trials. American Society of Clinical Oncology Annual Meeting; 1-5 Jun 2012; Chicago.

Friedlander M, Schofield P, Wilson K, Jefford M, Zannino D, Stockler M, Tebbutt N, Simes J, Wong N. Hope, optimism and survival in patients diagnosed with metastatic colorectal cancer (an Australasian Gastro-Intestinal Trials Group Study). MASCC/ISOO International Symposium; 23–25 Jun 2011; Athens.

Price T, Zannino D, Wilson K, van Hazel G, Robinson B, Broad A, Ganju V, Ackland S, Simes J, Tebbutt N. Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine, bevacizumab, and mitomycin C; first-line metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium; 20–22 Jan 2011; San Francisco. Abstract 510.

Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Outcome and dose intensity in the elderly subgroup of the AGITG MAX phase III trial of capecitabine, bevacizumab, and mitomycin C in first-line metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Schofield PE, Stockler MR, Zannino D, Wong N, Ransom D, Moylan EJ, Simes RJ, Price TJ, Tebbutt NC, Jefford M; on behalf of the Australasian GastroIntestinal Trials Group. Do hope, optimism and other psychological factors predict survival in patients with metastatic colorectal cancer? IPOS 13th World Congress of Psycho-Oncology; 16–20 Oct 2011; Antalya, Turkey.

Weickhardt AJ, Williams D, Lee C, Simes J, Murone C, Wilson K, Cummins M, Asadi K, Price TJ, Mariadason J, Tebbutt NC; Australasian Gastro-Intestinal Trials Group. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer: analysis of the phase III MAX study. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Price TJ, Hardingham J, Lee C, Weickhardt A, Townsend A, Wrin JW, Shivasami A, Cummins M, Murone C, Tebbutt N. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab ± mitomycin C in advanced colorectal cancer. ESMO Congress; 8–12 Oct 2010; Milan.

Schofield P, Stockler M, Zannino D, Wong N, Ransom D, Moylan E, Simes RJ, Price TJ, Tebbutt NC, Jefford M; Australasian Gastrointestinal Trials Group (AGITG). Hope, optimism and survival in a randomized trial of first line chemotherapy for patients with metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago.

Stockler M, Zannino D, Wilson K, Gebski V, Abdi EA, Strickland A, Lowenthal RM, Simes RJ, Price TJ, Tebbutt NC; Australasian Gastro-Intestinal Trials Group (AGITG). Patient-rated outcomes in a randomized trial of first line chemotherapy with capecitabine, bevacizumab, and mitomycin-C for metastatic colorectal cancer: the AGITG MAX trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago.

Tebbutt NC, Gebski V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J, Price T. International randomised phase III study of capecitabine, bevacizumab and mitomycin C in first line metastatic colorectal cancer: final results of the AGITG MAX trial. ECCO 15 and 34th ESMO Multidisciplinary Congress; 20–24 Sep 2009; Berlin.

Tebbutt NC, Gebski V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J, Price T. International randomised phase III study of capecitabine, bevacizumab, and mitomycin C in first-line treatment of metastatic colorectal cancer: final results of the AGITG MAX trial. Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4023.

Grimison PS, Tebbutt N, Price T, van Hazel G, Wilson K, Tunney V, Stockler M. Comparing utilities for advanced colorectal cancer valued from societal and cancer-patients’ perspectives using baseline data from the MAX study of the Australasian Gastro-Intestinal Trials Group (AGITG). Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 449.

Price T, Gebski V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K, Tunney V, Tebbutt N. International multicentre randomised phase II–III study of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer: final safety analysis of the AGITG MAX trial. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 4029.

Price TJ, Gebski V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K, Tunney V, Tebbutt N. AGITG MAX trial—capecitabine, bevacizumab, and mitomycin C in metastatic colorectal cancer: safety analysis of 400 patients in an international multi-centre randomized phase II–III study. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 449.

Price TJ, Gebski V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K , Tunney V, Tebbutt N. Safety analysis of an international multi-centre randomised phase II–III study of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer: AGITG MAX trial. 33rd Congress of the European Society for Medical Oncology; 12–16 Sep 2008; Stockholm. Annals of Oncology 2008; 19 (suppl. 8): viii127. Abstract 365P.

Stockler M, Grimison P, Price T, van Hazel G, Wilson K, Tunney V, Tebbutt N. Comparing utilities for advanced colorectal cancer valued from societal and cancer-patients’ perspectives using baseline data from the MAX study of the Australasian Gastro-Intestinal Trials Group. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago.

Wilson K, Munro SC, James R, Tebbutt N, Price TJ, Shapiro J, Wong N. Comparison of ethical and regulatory processes in two multicentre, multiregional oncology clinical trials: an Australian perspective. Clinical Research Excellence 08; 7–9 Aug 2008; Brisbane.

Grimison PS, Tebbutt N, Price T, van Hazel G, Wilson K, Tunney V, Stockler M. Comparing utilities for advanced colorectal cancer valued from societal and cancer-patients’ perspectives using baseline data from the MAX study of the Australasian Gastro-Intestinal Trials Group (AGITG). 35th Annual General Meeting of the Clinical Oncological Society of Australia; 14–17 Nov 2007; Adelaide.

Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX study: MAXimising a clinical trial. 28th Annual Meeting of the Society for Clinical Trials; 20–23 May 2007; Montreal.

Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX Study: MAXimising trial outcomes in a multi-centred, multi-regional clinical trial. International Clinical Trials Symposium; 24–26 Sep 2007; Sydney.

Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX study: MAXimising a clinical trial. Applied Clinical Trials 13th Annual European Summit; 17–19 Oct 2006; Amsterdam.

PA3

Vickers M, Tu D, Lee C, Wheatley-Price P, Parulekar W, GBrundage M, Moore M, Au H, O’Callaghan C, Jonker D, Ringash J, Goldstein D. Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): Abstract 4053.
PAN 1

Chua YJ, Karapetis CS, Gebski V, O’Connell R, Begbie S, Nott LM, Cronk MF, Underhill C, Abdi EA, Van Hagen T, Wong N, Hall M, Ferraro DA, Sjoquist KM, Santos C, Mackey JR, Goldstein D. Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil and leucovorin) treated patients with metastatic pancreatic cancer: the randomized phase II PAN1 study. Gastrointestinal Cancers Symposium; 16–18 Jan 2014; San Francisco.

Chua Y, Karapetis C, Underhill C, Nott L, Goldstein D, Cronk M, Gebski V, Wong N, Sjoquist K, Biankin A. PAN1: a randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract TPS4137

NABNEC

Chantrill LA, Lipton LR, Hofman M, Gebski V, Gill A, Markman B, Yip S, Karapetis CS, Pavlakis N, Wong SF, Ransom DT, Sjoquist KM, Nagrial A, Michael M, Rayani U, Oostendorp M, Simes J, Khasraw M. AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 18–20 Jan 2018; San Francisco.

PETACC 6

Price T, Martyn J, Gill R, Hruby G, Gormly K, Harvey J, Ng S, Tebbutt N. PETACC-6: preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 180. Abstract 284.

Schmoll H, Haustermanns K, Price TJ, Nordlinger B, Hofheinz R, Daisne J, Janssens JF, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth FW, Hannig CV, Zalcberg J, Tebbutt NC, Mauer M, Messina CG, Lutz M, Van Cutsem E. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine ±oxaliplatin in locally advanced rectal cancer: interim analysis for disease-free survival of PETACC 6. European Society for Medical Oncology Congress; 26–30 Sep 2014; Madrid.

Schmoll HJ, Haustermans K, Price TJ, Nordlinger B, Hofheinz R, Daisne JF, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth FWB, Hannig C, Zalcberg JR, Tebbutt NC, Mauer ME, Messina CGM, Lutz MP, Van Cutsem E. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 Jun 2014; Chicago.

Schmoll H, Haustermans K, Price T, Nordlinger B, Hofheinz R, Daisne J, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig C, Zalcberg J, Tebbutt N, Mauer M, Messina C, Lutz M, Van Cutsem E, for the EORTC GITCG A, AGITG, EORTC ROG, BGDO, FFCD,. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 3531.

Schmoll HJ, Price T, Haustermanns K, Nordlinger B, Hofheinz RD, Daisne JF, Janssens J, Schmidt P, Reinel H, van Cutsem E, EORTC GITCG, AIO, AGITG, EORTC ROG, BGDO, FFCD. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: response to the local treatment after chemoradiation and surgery as secondary endpoint. Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Onkologie; 18–22 Oct 2013; Vienna.

Quasar 2

Midgley RS, Love S, Potter V, Segelov E, Ferry DR, Weaver A, Scudder C, Grumett S, Julier P, Kerr DJ. Capecitabine ± bevacizumab in the adjuvant treatment of colorectal cancer: first and final toxicity results from the international phase III Quasar 2 trial. European Society for Medical Oncology (ESMO) 37th Annual Congress; 28 Sep–2 Oct 2012; Vienna.

Segelov E, Ransom D, Eek R, Begbie S, Price T, Chong G, Jeffery M, Platell C, Solomon M, Farmer C, Wilson K, Roff K, Simes J, Hewett P.. QUASAR2: A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

Frenel J, Carreira S, Goodall J, Roda-Perez D, Smith A, Mateo J, Ong M, Gasi-Tendefelt D, Yap TA, Attard G, Nava-Rodrigues D, Molife LR, Kaye SB, Banerji U, deBono JS. Serial next generation sequencing of CFDNA to monitor phase I targeted drug administration. European Society for Medical Oncology Congress; 26–30 Sep 2014; Madrid.

Midgley RS, Love S, Tomlinson I, Johnstone E, Scudder C, Pearson SR, Julier P, Domingo E, Church D, Pezzela F, Hu J, Segelov E, Weaver A, Kerr DJ. Final results from QUASAR2, a multicentre, international randomised phase III trial of capecitabine ± bevacizumab in the adjuvant setting of stage II/III colorectal cancer. European Society for Medical Oncology Congress; 26–30 Sep 2014; Madrid.

REGISTER

Kumar SS, Kirkpatrick CM, Mann KP, Ray JE, Graham GG, Williams KM, Day RO, Desai J. Imatinib PKPD relationship: Results from an ongoing study. Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT) Annual Scientific Meeting; 1–4 Dec 2013; Melbourne.

Desai J, Goldstein D, McArthur G, Hicks R, Fox S, Kotasek D, Kang YK, Bracken K, Gebski V, Zalcberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. The REGISTER study: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago.

Desai J, Kang YK, Kotasek D, Robinson B, McArthur GA, Hicks R, Fox SB, Gebski V, Mann B, Gill RK, Wollin B, Zalcberg JR, Goldstein D. REGISTER: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

SCOT

P Blinman, A Martin, M Jefford, D Goldstein, D Boadle, M Morris, N Tebbutt, C Aiken, E Segelov, J Paul, A Haydon, T Iveson, M Stockler. AGITG SCOT: Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? ASCO 2018

Saunders MP, Paul J, Crosby J, Brown G, Iveson T, Kerr R, Harkin A, Allan K, McQueen J, Pearson SR, Cassidy J, Medley LC, Raouf S, Harrison M, Brewster A, C. R, Ellis R, Thomas AL, Churn M, Maka N. SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 18–20 Jan 2018; San Francisco.

Iveson T, Kerr R, Saunders MP, Hollander NH, Tabernero J, Haydon AM, Glimelius B, Harkin A, Scudder C, Boyd K, Waterston AM, Medley LC, Wilson C, Ellis R, Essapen S, Dhadda AD, Harrison M, Falk S, Raouf S, Paul J. Final DFS results of the SCOT study: an international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. American Society of Clinical Oncology; 2–6 Jun 2017; Chicago.

Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA, Bonnetain F, Watanabe T, Boukovinas I, Renfro LA, Grothey A, Niedzwiecki D, Torri V, Andre T, Sargent DJ, Iveson T. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. American Society of Clinical Oncology Annual Meeting; 2–6 Jun 2017; Chicago.

Paul J, Briggs A, Harkin A, Haydon AM, Iveson T, Masterson M, Midgley RA, Cassidy J. SCOT: Short Course Oncology Therapy—A comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. Journal of Clinical Oncology 2011; 29 (suppl.). Abstract e14145.

Haydon A, Price T, Jefford M, Walpole E, Yip D, Ransom D, Jeffery M, Tebbutt N, Wong N, Wollin B, Segelov E. SCOT: Short Course Oncology Therapy—a study of adjuvant chemotherapy in colorectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

Segelov E, Haydon A, Price T, Jefford M, Walpole E, Yip D, Ransom D, Jeffery M, Tebbutt N, Wong N. SCOT: short course oncology therapy— a study of adjuvant chemotherapy in colorectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 181. Abstract 289.

SUPER

Platell C, Gebski V, Solomon M, Hewett P, Price T, Quiene S, Wilson K, Tebbutt N. The SUPER study: a randomised phase III multicentre study evaluating the role of palliative surgical resection of the primary tumour in patients with metastatic colorectal cancer. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.
TACTIC

Shannon J, Goldstein D, Wong N, Chinchen S, Sjoquist K, O’Connell R, Grimison P, McLachlan SA, Tebbutt NC, Lipton L, Vasey P., Cronk MF, Varma SC, Jefford M, Segelov E, Abdi E, Ng S, Karapetis C, Gebski V, Zalcberg J. A multicentre, phase II, open-label, single-arm trial of panitumumab, cisplatin and gemcitabine in biliary tract cancer: primary results of the AGITG TACTIC study. European Society for Medical Oncology Congress; 26–30 Sep 2014; Madrid.
TOPGEAR

Goldstein D, Fawcett J, Bridgewater JA, Choti M, Wilson K, Gebski V, Aiken C, Eminton Z, Falk S, Stanton L, Primrose JN. Feasibility of trials to assess safety and toxicity of peri-operative and post-operative adjuvant therapy for hepatic metastases from colorectal cancer. European Cancer Congress 2015; 25-29 Sep 2015; Vienna.

Verghis J, Miller D, Smithers BM, Murray WK, Crain M, Leong T. Conducting quality assurance processes in a multimodality treatment study involving chemoradiotherapy and surgery—measuring data integrity in the TOPGEAR trial. ACTA 2015 International Clinical Trials Symposium; 7–10 Oct 2015; Sydney.

Leong T, Smithers M, Michael M, Gebski V, Boussioutas A, Miller D, Zalcberg J, Wong R, Haustermans K. TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.

TROG 01.04

Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B, Ackland SP, Joseph DJ, McClure B, McLachlan SA, Mackay J. A randomized trial comparing local recurrence rates between short-course and long-course preoperative radiotherapy for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSA, RACS). American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago.

Ngan SY, McLachlan SA, Fisher R, Burmeister B, Joseph D, Hruby G, Ackland S, Ganju V, Mackay J, Solomon M. A comparison of quality of life in patients with rectal cancer receiving short course versus long course preoperative radiation. A Trans-Tasman Radiation Oncology Group, Australasian Gastrointestinal Trials Group, Colorectal Surgical Society of Australia and New Zealand, and Royal Australasian College of Surgeons trial. Royal Australian and New Zealand College of Radiologists 59th Annual Scientific Meeting; 16–19 Oct 2008; Adelaide.

Ngan S, Fisher R, Mackay J, Solomon M, Burmeister B, Goldstein D, Schache D, Joseph D, Ackland S, McClure B. Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04). 14th European Cancer Conference (ECCO); 23-27 Sep 2007; Barcelona.

Ngan S, Burmeister B, Fisher R, Joseph D, Solomon M, Schache D, Mackay J, Ackland S, Goldstein D, McClure B, McLachlan S, Dhillon H, Thompson P. A randomised trial of preoperative radiotherapy for stage T3 adenocarcinoma of the rectum (TROG 01.04): a progress report. International Conference on Radiation Research (ICRR); 17-22 Aug 2003; Brisbane.

Burmeister B, Smithers B, Fitzgerald L, Gebski V, Devitt P, Ackland S, Joseph D, Millar J, North J, Walpole E, Denham J. A randomized phase III trial of preoperative chemoradiation followed by surgery versus surgery alone for localized resectable cancer of the esophagus. American Society of Clinical Oncology Annual Meeting; 18–21 May 2002; Orlando.